Dairkee S H, Hackett A J
Peralta Cancer Research Institute, Oakland, CA.
Breast Cancer Res Treat. 1991 Mar;18(1):57-61. doi: 10.1007/BF01975444.
We have qualitatively evaluated the retention of the fluorescent dye rhodamine 123 by malignant or non-malignant breast epithelial cells in passively-infused fresh surgical specimens. Our findings demonstrate a microscopically-visible increase in the ability of primary and metastatic tumor cells to retain the dye, as compared to non-malignant epithelium. Some variability in fluorescence intensity was seen within and between tumor specimens. The optimal length of incubation in the presence of the dye was critical in achieving differential fluorescence intensity between normal and malignant cells. This method of examining rhodamine 123 uptake and retention in tissue explants provides a reliable means for direct, comparative visualization in situ of any tissue and its associated disorders. The results of this study also demonstrate the validity of extending the use of lipophilic, cationic compounds such as rhodamine 123 as antitumor agents, from model systems to the treatment of malignant disease.
我们已经对被动注入的新鲜手术标本中恶性或非恶性乳腺上皮细胞对荧光染料罗丹明123的保留情况进行了定性评估。我们的研究结果表明，与非恶性上皮细胞相比，原发性和转移性肿瘤细胞保留染料的能力在显微镜下可见增加。在肿瘤标本内部和之间观察到荧光强度存在一些差异。在染料存在下孵育的最佳时长对于实现正常细胞和恶性细胞之间的荧光强度差异至关重要。这种检查罗丹明123在组织外植体中的摄取和保留的方法为直接、原位比较可视化任何组织及其相关疾病提供了一种可靠手段。本研究结果还证明了将亲脂性阳离子化合物（如罗丹明123）作为抗肿瘤药物的使用从模型系统扩展到恶性疾病治疗的有效性。
